Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298723 | 0.84 | KDM4E (0.41) | MEN1KMT2AHPGDHTTL3MBTL1 | |
| SCHEMBL3498631 | 0.84 | MRGPRX4 (0.45) | KMT2AHTTTP53L3MBTL1TDP1 | |
| SCHEMBL5981851 | 0.81 | MAPT (0.50) | MEN1KMT2APKMHPGDHTT | |
| SCHEMBL5544931 | 0.80 | MEN1 (0.53) | MEN1KMT2APKMHPGDTP53 | |
| SCHEMBL4293680 | 0.79 | L3MBTL1 (0.44) | MEN1KMT2APKMHPGDHTT | |
| SCHEMBL5251072 | 0.77 | KMT2A (0.52) | MEN1KMT2AHPGDL3MBTL1TDP1 | |
| SCHEMBL2641277 | 0.76 | TDP1 (0.56) | HPGDHTTTDP1GAAMAPT | |
| SCHEMBL11331289 | 0.76 | ALDH1A1 (0.45) | MEN1KMT2ATDP1CYP1A2CYP2C19 | |
| SCHEMBL2092541 | 0.76 | MEN1 (0.52) | MEN1KMT2APKMHPGDHTT | |
| SCHEMBL514580 | 0.75 | CA12 (0.54) | MEN1KMT2AHTTRXRAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | claimed |
| EP-3601237-A2 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | Trucode Gene Repair, Inc. (US) | 2020-02-05 | — | — | EP | claimed |
| CN-110740994-A | Peptide Nucleic Acid (PNA) monomers with orthogonally protected ester moieties | 特鲁科德基因修复公司 | 2020-01-31 | — | — | CN | claimed |
| WO-2018175927-A2 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | TRUCODE GENE REPAIR, INC. (US) | 2018-09-27 | — | — | WO | claimed |
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | claimed |
| EP-2567964-A2 | Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection | Agilent Technologies, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| US-7759471-B2 | nucleotide monomer used to make protected RNA that has similar stability to the DNA molecule | AGILENT TECHNOLOGIES, INC. (US) | 2010-07-20 | — | — | US | claimed |
| EP-2001896-A2 | MONOMER COMPOSITIONS FOR THE SYNTHESIS OF RNA, METHODS OF SYNTHESIS, AND METHODS OF DEPROTECTION | Agilent Technologies, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | claimed |
| WO-2007112263-A2 | MONOMER COMPOSITIONS FOR THE SYNTHESIS OF RNA, METHODS OF SYNTHESIS, AND METHODS OF DEPROTECTION | AGILENT TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | WO | claimed |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | claimed |
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. | 2007-05-03 | — | — | US | claimed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | claimed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | claimed |
| US-6541626-B2 | Protecting/blocking the exocyclic amino function of purine nucleosides without effecting hydroxyl groups of sugar moieties via forming activated ester | ISIS PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | claimed |
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | ALLAHABAD, UNIVERSITY OF (IN) | 2003-01-30 | — | — | US | claimed |
| WO-2002083702-A1 | PROCESS FOR SELECTIVE N-ACYLATION OF PURINE NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | claimed |
| US-4178445-A | 7-(α-Substituted glycinamido)-3-substituted methyl-3-cephem-4-carboxylic acids and their derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-12-11 | — | — | US | claimed |
| WO-2024129931-A1 | ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-3953436-A | 3,4-Dicarboxycephalosporins and derivatives | ELI LILLY AND COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | MEN1 2153/4885KMT2A 558/4885PKM 3203/4885 |
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | RNGTT, RNMT, NSUN2 | MEN1 875/4885KMT2A 1745/4885PKM 1517/4885 |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | POLN, NT5C3B, PCNA | MEN1 838/4885KMT2A 3202/4885PKM 1324/4885 |
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | PNP, NUDT1, ADAR | MEN1 3497/4885KMT2A 2513/4885PKM 2503/4885 |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | MEN1 2159/4885KMT2A 1921/4885PKM 2477/4885 |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, RB1, ARG2 | MEN1 2153/4885KMT2A 558/4885PKM 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.